| 1. | Primary efficacy endpoints were overall survival and time to symptomatic progression
主要效果终端指标为总生存率和症状进展时间。 |
| 2. | Os overall survival
总生存时间 |
| 3. | The five - gene signature was an independent predictor of relapse - free and overall survival
这五个基因是对无复发和总生存率的独立预测指标。 |
| 4. | Clinical curing rate and the overall survival rate reduces along withthe lymph node shift rate increase
临床治愈率和整体生存率随淋巴结转移率的增加而降低。 |
| 5. | Conclusion : combination with repeat surgery and tmz improved overall survival of these gbm patients
结论反复手术联合手术后使用tmz可以提高gbm患者的总体存活时间。 |
| 6. | Conclusions our five - gene signature is closely associated with relapse - free and overall survival among patients with nsclc
结论：我们的五个基因标记与非小细胞肺癌患者的无复发及总生存率密切相关。 |
| 7. | For patients with pathologic complete response , neoadjuvant therapy may give additional benefit in prolonging overall survival
对于病理完全缓解的患者，新辅助治疗可以带来延长总体生存时间的益处。 |
| 8. | Both overall survival times were significantly influenced by age , tumor size , tumor location , surgical method , and surgical margin status
病人的存活与年龄、肿瘤的大小、肿瘤位置、手术方法及手术后病灶边缘状态有关。 |
| 9. | Most children diagnosed with cancer now survive - the overall survival beyond five years for pediatric cancer is more than 70 percent
随着医学技术的进步，大多数被确诊罹患癌症的孩子最终均可战胜病魔。儿童癌症患者的5年以上存活率目前已超过70 。 |
| 10. | The median overall survival time for patients in the avastin plus carboplatin and paclitaxel arm was 12 . 3 months versus 10 . 3 months for patients receiving only carboplatin and paclitaxel
阿瓦斯丁联合卡铂和紫杉醇的平均生存时间为12 . 3个月，与之相对的单用卡铂和紫杉醇的为10 . 3个月。 |
